Sandoz Group AG
0SAN.L
London Stock Exchange72.11
CHF
+0.40
- -
Sandoz Group AG
0SAN.L
(London Stock Exchange)
Recent
price
72.11
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Sandoz Group AG is a Switzerland-based global pharmaceutical company specializing in generic and biosimilar medicines. The company develops, manufactures, and markets a comprehensive portfolio including small molecule pharmaceuticals, finished dosage forms, anti-infectives, active pharmaceutical ingredients (APIs), biosimilars, and contract manufacturing organization (CMO) services. Sandoz serves over 100 countries worldwide across therapeutic areas such as oncology, immunology, dermatology, and cardiovascular diseases. Its products include around 1,300 medicines under various categories, supported by active pharmaceutical ingredients and intermediates production facilities primarily located in Europe and the United States. Founded as an independent company spun off from Novartis in 2023, it is headquartered in Basel, Switzerland, with a global B2B business unit operating from Kufstein, Austria. In recent major developments, Sandoz completed its spin-off from Novartis in October 2023, becoming a standalone publicly traded company. It inaugurated a new headquarters in Basel in November 2024 and expanded its biosimilars capabilities in 2025 by signing an agreement to acquire Just-Evotec Biologics EU SAS, a move to boost in-house biosimilar development and manufacturing. The acquisition involves Evotec’s proprietary continuous manufacturing technology platform and includes payments potentially totaling over $650 million. In early 2024, Sandoz acquired the biosimilar vision drug Cimerli from Coherus BioSciences for $170 million. It also reached patent dispute settlements with Amgen and resolved a U.S. generics class action lawsuit in 2024. Sandoz has been streamlining its manufacturing footprint, reducing sites from 18 to 15 by 2025 to optimize capacity and supply chain efficiency. It continues to launch new biosimilars such as Stelara biosimilar Pyzchiva and plans further launches like the Tysabri biosimilar Tyruko in the U.S. market. The company operates mainly within the generics and biosimilars pharmaceutical segments, targeting hospitals, healthcare providers, and retail pharmacies globally with a significant footprint in Europe, the United States, and emerging markets. Sandoz targets expanded patient access through its purpose of pioneering global medicine access, delivering approximately 800 million treatments annually. The company employs over 23,000 people worldwide and reported revenue of CHF 8.43 billion for the trailing twelve months as of mid-2025. Sandoz remains committed to innovation and strategic growth through portfolio expansion, technological advancements, and operational efficiencies, positioning itself as a leading player in affordable generic and biosimilar medicines with a broad global reach and robust pharmaceutical manufacturing capabilities.